8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
May 1, 2026·SEC
Material company update
Apr 28, 2026·SEC
Drugs Made In America Acquisition Corp. Ordinary Shares(DMAA)Earnings, Financials & Key Ratios
DMAA•NASDAQ•Banking & Credit
56.0× P/E·Price updated Jun 25, 2026
SectorFinancial ServicesIndustrySPACs & Shell CompaniesSub-IndustryHealthcare and life sciences SPACs
AboutDrugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.Show more
- Net Interest Income$9M
- Total Revenue$0
- Net Income$6M+1240317.7%
- Return on Equity5.11%
- Net Interest Margin3.65%
- ROA4.95%+105.7%
- Equity / Assets96.97%+319.0%
- Book Value per Share11.07+39549703.6%
DMAA Key Insights
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong NIM of 3.6%
- ✓Well capitalized: 97.0% equity/assets
- ✓Trading near 52-week high
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 100.0% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when DMAA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DMAA Price & Volume
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) stock price & volume — 10-year historical chart
Loading chart...
DMAA Growth Metrics
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM500.08%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-99.58%
Return on Capital
10 Years-2.35%
5 Years-2.35%
3 Years-2.35%
Last Year-2.35%
DMAA Peer Comparison
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) competitors in Healthcare and life sciences SPACs — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HCAI | 10.11M | 8.98 | -0.24 | -83.94% | -262.32% | 0.01 | ||
 BRTX | 3.54M | 0.39 | -0.25 | -10.3% | -30.9% | -423.84% | ||
 NUVB | 2.02B | 5.81 | -9.68 | 6.99% | -102.06% | -44.1% | 0.03 | |
 MRK | 309.84B | 125.45 | 17.23 | 1.18% | 13.62% | 17.91% | 0.96 | |
 PFE | 134.64B | 23.67 | 17.40 | -1.65% | 11.83% | 8.34% | 0.78 | |
 ABBV | 429.58B | 243.14 | 102.59 | 8.57% | 5.79% | 67.46% | ||
 BMY | 113.09B | 55.39 | 16.06 | -0.22% | 15.01% | 38.96% | 2.55 | |
 LLY | 1.07T | 1129.13 | 49.20 | 44.7% | 34.98% | 101.17% | 1.60 |
Compare DMAA vs Peers
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DMAA Income Statement
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'24 | Dec'25 | TTM |
|---|---|---|---|
Net Interest Income | 0 | 8.76M | 9.28M |
NII Growth % | - | - | 33.32% |
Net Interest Margin % | 0% | 3.65% | 3.84% |
Interest Income | 0 | 8.76M | 9.28M |
Interest Expense | 0 | 0 | 0 |
Loan Loss Provision | 0 | 0 | 0 |
Non-Interest Income | 0 | -8.76M | -9.28M |
Non-Interest Income % | - | - | - |
Total Revenue | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Revenue Growth % | - | - | 0% |
Non-Interest Expense | 480 | 2.82M | 2.63M |
Efficiency Ratio | - | - | - |
Operating Income | -479▲ 0% | -2.82M▼ 587794.2% | -2.63M▲ 0% |
Operating Margin % | - | - | - |
Operating Income Growth % | - | -587794.15% | - |
Pretax Income | -479▲ 0% | 5.94M▲ 1240317.7% | 6.66M▲ 0% |
Pretax Margin % | - | - | - |
Income Tax | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% |
Net Income | -479▲ 0% | 5.94M▲ 1240317.7% | 6.66M▲ 0% |
Net Margin % | - | - | - |
Net Income Growth % | - | 1240317.75% | 500.08% |
Net Income (Continuing) | -479 | 5.94M | 6.66M |
EPS (Diluted) | -0.06▲ 0% | 0.19▲ 439.3% | 0.29▲ 0% |
EPS Growth % | - | 439.29% | -99.58% |
EPS (Basic) | -0.06 | 0.19 | - |
Diluted Shares Outstanding | 8.57M | 21.01M | 23M |
DMAA Balance Sheet
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'24 | Dec'25 | TTM |
|---|---|---|---|
Cash & Short Term Investments | 1.35K | 6.14K | 22.56K |
Cash & Due from Banks | 1.35K | 6.14K | 14.89K |
Short Term Investments | 0 | 0 | 0 |
Total Investments | 0 | 0 | 242.02M |
Investments Growth % | - | - | 3.61% |
Long-Term Investments | 0 | 0 | 716.09M |
Accounts Receivables | 0 | 0 | 0 |
Goodwill & Intangibles | 0 | 0 | 0 |
Goodwill | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 |
PP&E (Net) | 0 | 0 | 0 |
Other Assets | 546 | 239.91M | 0 |
Total Current Assets | 4.99K | 12.19K | 14.89K |
Total Non-Current Assets | 546 | 239.91M | 242.02M |
Total Assets | 551▲ 0% | 239.92M▲ 43542340.5% | 242.04M▲ 0% |
Asset Growth % | - | 43556253.21% | 143611821.24% |
Return on Assets (ROA) | -86.96% | 4.95% | 2.79% |
Accounts Payable | 0 | 222.18K | 238.18K |
Total Debt | 662 | 0 | 100K |
Net Debt | 661 | -6.14K | 85.11K |
Long-Term Debt | 0 | 0 | 0 |
Short-Term Debt | 662 | 0 | 100K |
Other Liabilities | 0 | 6.9M | 6.9M |
Total Current Liabilities | 796 | 376.17K | 492.17K |
Total Non-Current Liabilities | 0 | 6.9M | 6.9M |
Total Liabilities | 796 | 7.28M | 7.39M |
Total Equity | -244▲ 0% | 232.64M▲ 95345458.6% | 234.64M▲ 0% |
Equity Growth % | - | 95345458.61% | 195485143.1% |
Equity / Assets (Capital Ratio) | -44.28% | 96.97% | 96.95% |
Return on Equity (ROE) | - | 5.11% | 2.88% |
Book Value per Share | -0.00 | 11.07 | 10.20 |
Tangible BV per Share | -0.00 | 11.07 | 10.20 |
Common Stock | 986 | 239.91M | 242.02M |
Additional Paid-in Capital | 34 | 0 | 0 |
Retained Earnings | -279 | -7.27M | -7.38M |
Accumulated OCI | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 |
Preferred Stock | 0 | 0 | 0 |
DMAA Cash Flow Statement
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) cash flow — operating, investing & free cash flow history
| Metric | Dec'24 | Dec'25 | TTM |
|---|---|---|---|
Cash from Operations | -172.26K | -539.19K | -379.19K |
Operating CF Growth % | - | -213% | -379099.69% |
Net Income | -479 | 3.97M | 6.66M |
Depreciation & Amortization | 0 | 0 | 0 |
Deferred Taxes | 0 | 0 | 0 |
Other Non-Cash Items | -171.92K | -4.65M | -5.1M |
Working Capital Changes | 132 | 138.85K | -22.07K |
Cash from Investing | 0 | -231.15M | 0 |
Purchase of Investments | 0 | 0 | 231.15M |
Sale/Maturity of Investments | 0 | 0 | 0 |
Net Investment Activity | 0 | 0 | 231.15M |
Acquisitions | 0 | 0 | 0 |
Other Investing | 0 | -231.15M | -231.15M |
Cash from Financing | 173.62K | 231.69M | 393.16K |
Dividends Paid | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 |
Stock Issued | -328.6K | 232.05M | -232.05M |
Net Stock Activity | -328.6K | 232.05M | -232.05M |
Debt Issuance (Net) | 502.21K | -900K | 1M |
Other Financing | 1 | 543.97K | 231.44M |
Net Change in Cash | 1.35K▲ 0% | 4.79K▲ 254.3% | 12.79K▲ 0% |
Exchange Rate Effect | 0 | 0 | 0 |
Cash at Beginning | 0 | 1.35K | 6.14K |
Cash at End | 1.35K | 6.14K | 14.89K |
Interest Paid | 0 | 0 | 0 |
Income Taxes Paid | 0 | 0 | 0 |
Free Cash Flow | -295▲ 0% | -539.19K▼ 182675.3% | -379.19K▲ 0% |
FCF Growth % | - | -182675.25% | -22.83% |
DMAA Banking Ratios
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2025 | TTM |
|---|---|---|
Return on Equity (ROE) | 5.11% | 2.88% |
Return on Assets (ROA) | 4.95% | 2.79% |
Net Interest Margin | 3.65% | 3.84% |
Equity / Assets | 96.97% | 96.95% |
Book Value / Share | 11.07 | 10.2 |
NII Growth | - | 485.63% |
Dividend Payout | - | 0% |
Related:DMAA Dividend History·DMAA Revenue History·DMAA Price History·DMAA P/E History·DMAA Financial Ratios·DMAA Institutional Holders
DMAA SEC Filings & Documents
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) SEC filings — annual & quarterly reports (10-K, 10-Q)
DMAA Frequently Asked Questions
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) is profitable, generating $6.7M in net income for fiscal year 2025.
Dividend & Returns
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a return on equity (ROE) of 5.1%. This is below average, suggesting room for improvement.
Industry Metrics
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a net interest margin (NIM) of 3.6%. This indicates healthy earnings from lending activities.
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has an efficiency ratio of 0.0%. This is excellent, indicating strong cost control.